Dimephosphone® (Dimephosphon)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceDimethyloxobutylphosphonyl dimethylateDimethyloxobutylphosphonyl dimethylate
Similar drugsTo uncover
  • Dimephosphone®
    solution inwards externally 
    TATHIMFARMPREPARATY, JSC     Russia
  • Dimephosphone®
    concentrate in / in 
    TATHIMFARMPREPARATY, JSC     Russia
    • Dosage form: & nbspConcentrate for the preparation of a solution for intravenous administration.
    Composition:

    1 ampoule contains:
    Active substance: Dimethyl oxobutylphosphonyl dimethylate (Dimefosfon®) 1.0 g.

    Description:

    Colorless or yellowish transparent liquid with a peculiar odor.

    Pharmacotherapeutic group:Anti-acid drug.
    ATX: & nbsp
  • Other medications
    • Pharmacodynamics:

    Dimefosfon shows anti-acid, membrane-stabilizing, anti-inflammatory and antioxidant properties, normalizes blood flow and metabolism of brain tissues, reduces cardiac and pulmonary insufficiency, improves blood circulation regulation, including cerebral circulation.

    Anti-acid effect is realized due to intensification of renal and pulmonary mechanisms of regulation of acid-base state, enhancement of intraorganic blood flow and tissue metabolism, and dimephosfon reduces the content of lactic and pyruvic acids in the brain tissues.

    Dimefosfon stabilizes cell membranes, restoring reactivity of cerebral vessels,improving the functions of the cerebral hemispheres and the brain stem, reduces the depth of disturbances in consciousness, restores the sleep-wake cycle, reflexes, arcs that close through the stem divisions, reduces the severity of pyramidal, cerebellar, vestibular, visual and auditory disorders.

    Antioxidant action is carried out by preventing the activation of lipid peroxidation and increasing the activity of antioxidant enzymes in the brain tissues.

    Dimefosfon strengthens the energy processes in the brain as directly, directly affecting the mitochondria, and indirectly by stimulating the pituitary-thyroid system, increasing the consumption of thyroid hormones by tissues, which is accompanied by activation of energy and catabolic processes in the mitochondria of cells. It shows the properties of some neurotransmitters (GABA-positive, H-cholino and dopaminergic activity).

    Dimefosfon reduces cardiac and pulmonary insufficiency, restoring the resistivity of peripheral vessels (arterial and venous).

    Dimefosfon improves the regulation of cerebral circulation, not having a pronounced vasodilating effect,but positively affects the metabolism of brain tissues during their ischemia, improves venous outflow. The effectiveness of clinical use of the drug for various forms of cerebrovascular insufficiency is associated with its ability to increase the resistance of nerve cells to ischemia, with a decrease in edema and, in connection with this, improvement in microcirculation.

    Pharmacokinetics:

    Easily passes through the histohematological barriers and is distributed to various organs and tissues. The greatest concentrations are created in the brain, heart and spleen. Three days after the single administration of Dimefosfon, only trace concentrations remain in the body.

    Dimefosfon is excreted unchanged mainly with urine in the amount of 11-15% of the drug (up to 70% of the withdrawn amount of the drug is released within the first 12 hours).

    Indications:

    As part of complex therapy:
    Chronic disorders of cerebral circulation, in the intermediate and distant period of craniocerebral and neurosurgical injuries, the consequences of ischemic and hemorrhagic strokes, Meniere's disease.

    Contraindications:

    Epilepsy, chronic renal failure 2-3 degrees (creatinine clearance less than 40 ml / min), individual intolerance, children under 18 years.

    Carefully:


    Pregnancy and lactation:

    Strictly controlled clinical studies of the safety of the use of Dimefosfon ® during pregnancy and during breastfeeding were not carried out.

    Currently, data on the use of the drug Dimefosfon® concentrate for the preparation of a solution for intravenous administration in pregnancy is not enough to assess the teratogenic effect of dimephosphone.

    Therefore, Dimefosfon® concentrate for the preparation of a solution for intravenous administration should be given during pregnancy and during breastfeeding only if the intended benefit from its use exceeds the potential risk to the fetus or infant.

    Studies in animals have not revealed a damaging effect on the embryo and its development.

    Dosing and Administration:

    In complex therapy:
    Chronic disorders of cerebral circulation, in the intermediate and distant period of craniocerebral and neurosurgical injuries:
    intravenously - 1 g (1 ampoule) of the drug diluted in 10-20 ml of sterile water for injection or 0.9% solution of sodium chloride 1-4 times a day for 10-14 days.
    or intravenously drip - 1 g (1 ampoule) of the drug diluted in 200-400 ml of sterile water for injection or 0.9% solution of sodium chloride 1-4 times a day for 10-14 days.

    Consequences of ischemic and hemorrhagic strokes:
    intravenously - 1-2 g (1-2 ampoules) of the drug diluted in 10-20 ml of sterile water for injection or 0.9% solution of sodium chloride 1-4 times a day for 10-15 days;

    or intravenously drip - 1-2 grams (1-2 ampoules) of the drug, diluted in 200-400 ml of sterile water for injection or 0.9% solution of sodium chloride 1-4 times a day for 10-15 days.

    Ménière's Disease:
    intravenously - 1 g (1 ampoule) of the drug diluted in 10 ml of 0.9% sodium chloride solution 1-3 times a day for 10 days, then it is recommended to continue the course of treatment with the drug Dimefosfon ®, solution for ingestion and external application, in accordance with the instructions for use.

    Side effects:

    Drowsiness and worsening of concentration of attention (3-4 days after the first injection of the drug pass).

    Overdose:

    Symptoms: increased severity of side effects.
    Treatment: symptomatic therapy.

    Interaction:

    Interactions with other drugs have not been identified.

    Special instructions:

    At occurrence of drowsiness in the first days of reception of a preparation it is necessary to refrain from driving of motor transport and employment demanding the raised attention and high speed of psychomotor reactions.

    Strictly controlled clinical studies of the safety of the use of Dimefosfon ® in children have not been conducted.

    Effect on the ability to drive transp. cf. and fur:

    When using the drug should refrain from the management of vehicles and occupations that require increased attention and reaction speed.

    Form release / dosage:

    Concentrate for the preparation of a solution for intravenous administration of 1.0 g.

    Packaging:

    For 1 g of the drug in ampoules of colorless glass.

    5 ampoules are placed in a contour cell pack.

    1 or 2 outline cell pack together with the instructions for use are placed in a cardboard box.

    Storage conditions:

    In the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:3 years.

    Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-003523
    Date of registration:24.03.2016
    Expiration Date:24.03.2021
    The owner of the registration certificate:TATHIMFARMPREPARATY, JSC TATHIMFARMPREPARATY, JSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp21.08.16
    Illustrated instructions
      Instructions
      Up